185 related articles for article (PubMed ID: 30549425)
1. Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18.
Stehlik J; Armstrong B; Baran DA; Bridges ND; Chandraker A; Gordon R; De Marco T; Givertz MM; Heroux A; Iklé D; Hunt J; Kfoury AG; Madsen JC; Morrison Y; Feller E; Pinney S; Tripathi S; Heeger PS; Starling RC
Am J Transplant; 2019 May; 19(5):1518-1528. PubMed ID: 30549425
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.
Starling RC; Stehlik J; Baran DA; Armstrong B; Stone JR; Ikle D; Morrison Y; Bridges ND; Putheti P; Strom TB; Bhasin M; Guleria I; Chandraker A; Sayegh M; Daly KP; Briscoe DM; Heeger PS;
Am J Transplant; 2016 Jan; 16(1):121-36. PubMed ID: 26260101
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients.
Daly KP; Stack M; Eisenga MF; Keane JF; Zurakowski D; Blume ED; Briscoe DM
J Heart Lung Transplant; 2017 Apr; 36(4):434-442. PubMed ID: 27865734
[TBL] [Abstract][Full Text] [Related]
4. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.
Daly KP; Seifert ME; Chandraker A; Zurakowski D; Nohria A; Givertz MM; Karumanchi SA; Briscoe DM
J Heart Lung Transplant; 2013 Jan; 32(1):120-8. PubMed ID: 23260712
[TBL] [Abstract][Full Text] [Related]
5. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
[TBL] [Abstract][Full Text] [Related]
7. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
[TBL] [Abstract][Full Text] [Related]
8. Association of Endothelin-1 With Accelerated Cardiac Allograft Vasculopathy and Late Mortality Following Heart Transplantation.
Parikh RV; Khush K; Pargaonkar VS; Luikart H; Grimm D; Yu M; Okada K; Honda Y; Yeung AC; Valantine H; Fearon WF
J Card Fail; 2019 Feb; 25(2):97-104. PubMed ID: 30543947
[TBL] [Abstract][Full Text] [Related]
9. Ischemic cardiomyopathy is associated with coronary plaque progression and higher event rate in patients after cardiac transplantation.
Guddeti RR; Matsuo Y; Matsuzawa Y; Aoki T; Lennon RJ; Lerman LO; Kushwaha SS; Lerman A
J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25095871
[TBL] [Abstract][Full Text] [Related]
10. Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation.
Starling RC; Armstrong B; Bridges ND; Eisen H; Givertz MM; Kfoury AG; Kobashigawa J; Ikle D; Morrison Y; Pinney S; Stehlik J; Tripathi S; Sayegh MH; Chandraker A;
J Am Coll Cardiol; 2019 Jul; 74(1):36-51. PubMed ID: 31272550
[TBL] [Abstract][Full Text] [Related]
11. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort.
Arnaoutakis GJ; George TJ; Kilic A; Weiss ES; Russell SD; Conte JV; Shah AS
J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1236-45, 1245.e1. PubMed ID: 21839482
[TBL] [Abstract][Full Text] [Related]
12. Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation.
See SB; Clerkin KJ; Kennel PJ; Zhang F; Weber MP; Rogers KJ; Chatterjee D; Vasilescu ER; Vlad G; Naka Y; Restaino SW; Farr MA; Topkara VK; Colombo PC; Mancini DM; Schulze PC; Levin B; Zorn E
J Heart Lung Transplant; 2017 Aug; 36(8):862-870. PubMed ID: 28431981
[TBL] [Abstract][Full Text] [Related]
13. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Asymmetric Dimethylarginine to Predict Outcomes After Heart Transplantation.
Parikh RV; Khush K; Luikart H; Sakarovitch C; Lee J; Desai M; Valantine H; Yeung AC; Fearon WF
Am J Cardiol; 2018 Nov; 122(10):1707-1711. PubMed ID: 30220417
[TBL] [Abstract][Full Text] [Related]
15. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome.
Yamani MH; Haji SA; Starling RC; Tuzcu EM; Ratliff NB; Cook DJ; Abdo A; Crowe T; Secic M; McCarthy P; Young JB
J Am Coll Cardiol; 2002 Mar; 39(6):970-7. PubMed ID: 11897438
[TBL] [Abstract][Full Text] [Related]
16. Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance.
Svobodova E; Gazdic T; Kubanek M; Vymetalova J; Voska L; Kment M; Lanska V; Kolesar L; Urban M; Netuka I; Pirk J; Melenovsky V; Kautzner J; Slavcev A; Malek I
Transpl Int; 2016 Jan; 29(1):63-72. PubMed ID: 26340387
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
18. Impact of coronary endothelial dysfunction on adverse long-term outcome after heart transplantation.
Kübrich M; Petrakopoulou P; Kofler S; Nickel T; Kaczmarek I; Meiser BM; Reichart B; von Scheidt W; Weis M
Transplantation; 2008 Jun; 85(11):1580-7. PubMed ID: 18551063
[TBL] [Abstract][Full Text] [Related]
19. Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation.
Zuckerman WA; Zeevi A; Mason KL; Feingold B; Bentlejewski C; Addonizio LJ; Blume ED; Canter CE; Dipchand AI; Hsu DT; Shaddy RE; Mahle WT; Demetris AJ; Briscoe DM; Mohanakumar T; Ahearn JM; Iklé DN; Armstrong BD; Morrison Y; Diop H; Odim J; Webber SA
Am J Transplant; 2018 Sep; 18(9):2135-2147. PubMed ID: 29446208
[TBL] [Abstract][Full Text] [Related]
20. Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients.
Clemmensen TS; Koefoed-Nielsen P; Jensen LA; Poulsen SH; Holm NR; Løgstrup BB; Christiansen EH; Dijkstra J; Valen KPB; Eiskjaer H
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28627046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
